Larimar Therapeutics Inc

LRMR

Company Profile

  • Business description

    Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

  • Contact

    Three Bala Plaza East
    Suite 506
    Bala CynwydPA19004
    USA

    T: +1 844 511-9056

    https://www.larimartx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    65

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,934.3045.10-0.50%
CAC 407,834.5816.300.21%
DAX 4024,217.5078.43-0.32%
Dow JONES (US)44,897.47203.560.46%
FTSE 1009,120.3118.06-0.20%
HKSE25,388.35278.83-1.09%
NASDAQ21,127.6269.660.33%
Nikkei 22541,456.23370.11-0.88%
NZX 50 Index12,853.4648.330.38%
S&P 5006,391.3027.950.44%
S&P/ASX 2008,666.9042.50-0.49%
SSE Composite Index3,593.6612.07-0.33%

Market Movers